Nothing Special   »   [go: up one dir, main page]

MX2021008958A - Proteínas de unión a antígeno del receptor gamma anti-il2. - Google Patents

Proteínas de unión a antígeno del receptor gamma anti-il2.

Info

Publication number
MX2021008958A
MX2021008958A MX2021008958A MX2021008958A MX2021008958A MX 2021008958 A MX2021008958 A MX 2021008958A MX 2021008958 A MX2021008958 A MX 2021008958A MX 2021008958 A MX2021008958 A MX 2021008958A MX 2021008958 A MX2021008958 A MX 2021008958A
Authority
MX
Mexico
Prior art keywords
receptor gamma
antibodies
binding proteins
antigen
fragments
Prior art date
Application number
MX2021008958A
Other languages
English (en)
Inventor
Jamie M Orengo
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021008958A publication Critical patent/MX2021008958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión a antígeno (por ejemplo, anticuerpos humanos) que se unen específicamente al receptor gamma de IL2 humana (IL2R). También se proporcionan métodos para tratar o prevenir enfermedades mediadas por IL2R (por ejemplo, enfermedad de injerto contra huésped) usando los anticuerpos y fragmentos junto con métodos para fabricar los anticuerpos y fragmentos.
MX2021008958A 2019-02-01 2020-01-30 Proteínas de unión a antígeno del receptor gamma anti-il2. MX2021008958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799851P 2019-02-01 2019-02-01
PCT/US2020/015841 WO2020160242A1 (en) 2019-02-01 2020-01-30 Anti-il2 receptor gamma antigen-binding proteins

Publications (1)

Publication Number Publication Date
MX2021008958A true MX2021008958A (es) 2021-11-04

Family

ID=69740681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008958A MX2021008958A (es) 2019-02-01 2020-01-30 Proteínas de unión a antígeno del receptor gamma anti-il2.

Country Status (15)

Country Link
US (2) US11629195B2 (es)
EP (1) EP3917962A1 (es)
JP (1) JP7544724B2 (es)
KR (1) KR20210123350A (es)
CN (1) CN113474370A (es)
AU (1) AU2020214812A1 (es)
BR (1) BR112021014074A2 (es)
CA (1) CA3126117A1 (es)
CL (1) CL2021002008A1 (es)
CO (1) CO2021009693A2 (es)
EA (1) EA202192090A1 (es)
IL (1) IL284579A (es)
MX (1) MX2021008958A (es)
SG (1) SG11202107272SA (es)
WO (1) WO2020160242A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474370A (zh) * 2019-02-01 2021-10-01 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白
US11834485B2 (en) * 2020-04-21 2023-12-05 Regeneron Pharmaceuticals, Inc. IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
CN118251416A (zh) * 2021-11-02 2024-06-25 上海岸迈生物科技有限公司 抗cd122抗体、抗cd132抗体及相关的双特异性结合蛋白
CN114990206B (zh) * 2022-06-02 2023-04-07 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Common γ-chain受体作为药物靶点在制备治疗狼疮性肾炎药物中的应用
WO2024015418A1 (en) 2022-07-13 2024-01-18 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes
WO2024073606A1 (en) 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. Antibody resistant modified receptors to enhance cell-based therapies
WO2024138175A1 (en) * 2022-12-22 2024-06-27 Forte Subsidiary, Inc. Methods of treating acute and chronic graft versus host diseases
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
WO1997017360A2 (en) 1995-11-09 1997-05-15 Dana-Farber Cancer Institute Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain
WO1997043416A1 (en) 1996-05-10 1997-11-20 Biogen, Inc. Common gamma chain blocking agents
US6861227B2 (en) 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
WO2001077288A2 (en) 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
WO2012096994A2 (en) 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
PE20150650A1 (es) 2012-09-12 2015-05-26 Genzyme Corp Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
DK3172227T3 (da) 2014-07-21 2019-12-02 Delinia Inc Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
CN115925939A (zh) * 2015-08-06 2023-04-07 新加坡科技研究局 IL2Rβ/通用γ链抗体
WO2017070561A1 (en) * 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2018156649A1 (en) 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
CN113474370A (zh) * 2019-02-01 2021-10-01 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白

Also Published As

Publication number Publication date
CA3126117A1 (en) 2020-08-06
EA202192090A1 (ru) 2021-10-20
CN113474370A (zh) 2021-10-01
JP7544724B2 (ja) 2024-09-03
WO2020160242A1 (en) 2020-08-06
US20230279131A1 (en) 2023-09-07
AU2020214812A1 (en) 2021-09-23
BR112021014074A2 (pt) 2021-11-23
CL2021002008A1 (es) 2022-02-04
SG11202107272SA (en) 2021-07-29
EP3917962A1 (en) 2021-12-08
US20200247894A1 (en) 2020-08-06
KR20210123350A (ko) 2021-10-13
IL284579A (en) 2021-08-31
JP2022519068A (ja) 2022-03-18
CO2021009693A2 (es) 2021-08-09
US11629195B2 (en) 2023-04-18

Similar Documents

Publication Publication Date Title
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA202091747A1 (ru) Составы антитела b7-h4
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
MY200162A (en) Anti-gitr antibodies and uses thereof
MX2022002682A (es) Anticuerpos anti-cd73.
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2023014389A (es) Anticuerpos anti-sirp-alfa.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
PH12021551195A1 (en) Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
MX2020013243A (es) Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.
MX2022014736A (es) Anticuerpos anti-cd200r1 y metodos de uso de estos.
MX2023012739A (es) Anticuerpos anti-gitr y usos de estos.
EA202190818A1 (ru) Комбинированная терапия онкологического заболевания